Safety and Efficacy of Two Doses of ATIR101, a T-lymphocyte Enriched Leukocyte Preparation Depleted of Host Alloreactive T-cells, in Patients With a Hematologic Malignancy Who Received a Hematopoietic Stem Cell Transplantation From a Haploidentical Donor

NCT ID: NCT02500550

Last Updated: 2021-05-18

Basic Information

• Recruitment Status: COMPLETED
• Clinical Phase: PHASE2
• Total Enrollment: 15 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2015-10-09
• Study Completion Date: 2018-12-17

Brief Summary

The purpose of this study is to determine whether a repeat dose administration of ATIR101 is safe and effective when infused in patients with a hematologic malignancy following a T-cell depleted stem cell graft from a related haploidentical donor. All patients are planned to receive two ATIR101 doses of 2×10E6 viable T-cells/kg, unless the second dose is reduced or halted for safety reasons.

Detailed Description

Study CR-AIR-008 is an exploratory, open-label, multicenter study. After signing informed consent, patients will receive a hematopoietic stem cell transplantation (HSCT) from a related, haploidentical donor, followed by a first ATIR101 infusion at a dose of 2×10E6 viable T-cells/kg between 28 and 32 days after the HSCT. Patients will receive a second ATIR101 infusion at a dose of 2×10E6 viable T-cells/kg between 70 and 74 days after the HSCT. To evaluate safety of the second dose administration, the first 6 patients treated will be evaluated for the occurrence of dose limiting toxicity (DLT), defined as acute GvHD grade III/IV within 120 days post HSCT (or within 42 days after the second ATIR101 infusion in case of prior dose delays). If within the first 6 patients no DLT is observed, treatment of the remaining 9 patients will continue with two ATIR101 doses of 2×10E6 viable T cells/kg. If within the first 6 patients at least 2 patients show DLT, the second ATIR101 infusion will be adjusted to a dose of 1×10E6 viable T cells/kg. If in one of the next 3 patients treated at this lower dose again DLT is observed, the second ATIR101 infusion will be halted and the remaining patients will be given only a single dose of ATIR101.

All patients treated with ATIR101 will be followed up until 12 months after the HSCT. Assessments will be performed at weekly visits from the day of the first ATIR101 infusion (Week 4) until 6 weeks after the second ATIR101 infusion (Week 16), at monthly visits from 4 until 6 months after the HSCT, and every 3 months from 6 until 12 months after the HSCT.

Conditions

Acute Myeloid Leukemia; Acute Lymphoblastic Leukemia; Myelodysplastic Syndrome

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: PREVENTION
• Blinding Strategy: NONE

Study Groups

ATIR101

Group Type: EXPERIMENTAL

ATIR101

Intervention Type: BIOLOGICAL

T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).

Haploidentical hematopoietic stem cell transplantation (HSCT)

Intervention Type: PROCEDURE

CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:

• Total Body Irradiation (TBI) regime
• Non-TBI regime

(See below for details)

TBI regime

Intervention Type: PROCEDURE

• Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)
• Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3
• Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7
• Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.

Non-TBI regime

Intervention Type: PROCEDURE

• Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4
• Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7
• Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1
• ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.

Interventions

ATIR101

T-lymphocyte enriched leukocyte preparation depleted ex vivo of host alloreactive T-cells (using photodynamic treatment). Two intravenous infusions with 2x10E6 viable T-cells/kg approximately 42 days apart (unless the second dose is reduced or halted for safety reasons).

Intervention Type: BIOLOGICAL

Haploidentical hematopoietic stem cell transplantation (HSCT)

CD34-selected HSCT from a haploidentical donor. In order to prepare the patient for the HSCT one of the following myeloablative conditioning regimens is recommended:

• Total Body Irradiation (TBI) regime
• Non-TBI regime

(See below for details)

Intervention Type: PROCEDURE

TBI regime

• Fractionated TBI 200 cGy twice daily for 3 days on Day -10 to -8 (1200 cGy in 6 fractions)
• Fludarabine 30 mg/m2 IV once daily for 5 days on Day -7 to -3
• Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7
• Anti-thymocyte globulin (ATG; Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.

Intervention Type: PROCEDURE

Non-TBI regime

• Fludarabine; 30 mg/m2 IV once daily for 5 days on Day -8 to -4
• Thiotepa; 5 mg/kg IV twice daily for 1 day on Day -7
• Melphalan; 60 mg/m2 IV once daily for 2 days on Day -2 and -1
• ATG (Thymoglobulin®); 2.5 mg/kg once daily for 4 days on Day -5 to -2, as a continuous IV infusion for 8 hours. During the course of ATG, patients will receive methylprednisolone 2 mg/kg/day IV.

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

• Any of the following hematologic malignancies:

• Acute myeloid leukemia (AML) in first remission with high-risk features or in second or higher remission
• Acute lymphoblastic leukemia (ALL) in first remission with high-risk features or in second or higher remission
• Myelodysplastic syndrome (MDS): transfusion-dependent, or intermediate or higher IPSS-R risk group
• Karnofsky performance status ≥ 70%
• Eligible for haploidentical stem cell transplantation according to the investigator
• Male or female, age ≥ 18 years and ≤ 65 years

• Haploidentical family donor with 2 to 3 mismatches at the HLA-A, -B and/or -DR loci of the unshared haplotype
• Male or female, age ≥ 16 and ≤ 75 years (If applicable, local legal requirements for donors under the age of 18 will be followed)
• Eligible for donations of human blood and blood components according to local requirements and regulations
• Eligible for donation according to the transplantation center

Exclusion Criteria

• Availability of a fully matched related or unrelated donor following a donor search
• Diffusing capacity for carbon monoxide (DLCO) < 50% predicted
• Left ventricular ejection fraction < 50% (evaluated by echocardiogram or MUGA)
• AST > 2.5 x ULN (CTCAE grade 2)
• Bilirubin > 1.5 x ULN (CTCAE grade 2)
• Creatinine clearance < 50 mL/min (calculated or measured)
• Positive HIV test
• Positive pregnancy test (women of childbearing age only)
• Prior allogeneic HSCT
• Estimated probability of surviving less than 3 months
• Known allergy to any of the components of ATIR101 (e.g., dimethyl sulfoxide)
• Known presence of HLA antibodies against the non-shared donor haplotype
• Any other condition which, in the opinion of the investigator, makes the patient ineligible for the study

• Positive pregnancy test or nursing (women of childbearing age only)
• Positive viral test for HIV-1, HIV-2, HBV, HCV, Treponema pallidum, HTLV 1 (if tested), HTLV-2 (if tested), or WNV (if tested)

• Minimum Eligible Age: 18 Years
• Maximum Eligible Age: 65 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: No

Sponsors

Kiadis Pharma

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Principal Investigators

Denis Claude Roy, Prof MD

Role: PRINCIPAL_INVESTIGATOR

Maisonneuve-Rosemont Hospital (Montreal, Canada)

Stephan Mielke, Prof MD

Role: PRINCIPAL_INVESTIGATOR

Centre for Allogeneic Stem Cell Transplantation, Karolinska University Hospital (Stockholm, Sweden)

Locations

Algemeen Ziekenhuis Sint-Jan

Bruges, , Belgium

Institut Jules Bordet

Brussels, , Belgium

Universitair Ziekenhuis Gasthuisberg

Leuven, , Belgium

Centre Hospitalier Universitaire de Liège

Liège, , Belgium

Juravinski Hospital and Cancer Centre

Hamilton, Ontario, Canada

Maisonneuve-Rosemont Hospital

Montreal, Quebec, Canada

University Hospital Centre Zagreb

Zagreb, , Croatia

University Medical Center Mainz

Mainz, , Germany

Hospital de Santa Maria, Clinica Universitaria Hematologia

Lisbon, , Portugal

Heartlands Hospital

Birmingham, , United Kingdom

Hammersmith Hospital

London, , United Kingdom

Countries

Belgium; Canada; Croatia; Germany; Portugal; United Kingdom

Provided Documents

Document Type: Study Protocol

View Document

Document Type: Statistical Analysis Plan

View Document

Other Identifiers

CR-AIR-008

Identifier Type: -

Identifier Source: org_study_id